Race Oncology Ltd

RAC

Race Oncology Ltd. is a precision oncology company, which engages in the discovery and development of the phase 2/3 cancer drug called Zantrene. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. Zantrene is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. The firm is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. Zantrene (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a cardio-protective chemotherapeutic. The firm also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Radiopharm Theranostics Limited

RAD

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm is focused on developing and commercializing radiopharmaceutical products and nuclear medicines for both therapeutic and diagnostic applications in precision oncology. The Company’s subsidiary includes Radiopharm Theranostics (USA) Inc. The firm has a pipeline of four licensed platform technologies, Nano-monoclonal antibodies (mAbs), Pivalate, AVβ6 Integrin and PSA-mAb. Nano-mAbs technology platform provides Nano-mAbs, which are made using genetically engineered camelid derived single domain antibodies (sdAb), that are labelled with radioisotopes to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Pivalate is an F-FPIA radiotracer, and its technology is based on a short chain carbohydrate. Its pipeline consists of RAD101, RAD102, RAD104, RAD105, RAD106, RAD201, RAD202, RAD204, RAD205, RAD207, RAD301, RAD302, RAD401 and RAD402.

Regener8 Resources NL

R8R

Regener8 Resources NL engages in raising seed capital to fund the company’s activities. The company is headquartered in Perth, Western Australia. The company went IPO on 2022-07-08. The firm operates Kookynie Gold Project (the Project), which comprises one exploration license and eight prospecting licenses located in the Kookynie region in Western Australia’s Goldfields region. The Kookynie Gold Project is located in the northern Goldfields region of Western Australia, covering an area of approximately 15 square kilometers (km2) within the North Coolgardie Mineral Field. The Project is approximately 150 kilometers (km) north of Kalgoorlie and 55km south of Leonora Township, and 50 km northeast of Menzies.